THIRONA BIO

We are focused on the development of novel drugs, targeting TGF-β, for the treatment of fibrotic diseases. We use a potent, topically applied drug, to inhibit TGF-β for the treatment of skin and lung fibrosis. The drug has been specifically engineered to act locally, thereby minimizing the potential risks of systemic exposure with this target.

Also known as: Thirona Bio, Inc.

Primary location: San Diego United States